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Introduction: Although the prognostic value of rheumatoid factor (RF) and autoantibodies against citrullinated
proteins (ACPAs) in patients with rheumatoid arthritis (RA) is well established, their association with RA disease
activity remains unclear. Here, we investigate this association in a large study using data from clinical trials.
Methods: We used baseline data from four recent randomized controlled clinical trials of RA. We investigated
individual and composite measures of disease activity. The relationship of RF and ACPAs with these measures was
investigated by using stratified analysis (comparing four groups of patients according to the presence or absence
of RF and ACPAs) and matched analysis (disease activity levels compared between patients negative and patients
highly positive for one autoantibody who were matched for levels of the other autoantibody as well as for age,
gender, and duration of RA).
Results: A total of 2118 patients were analysed in the different cohorts. In the stratified analysis, RF+ patients,
regardless of ACPA status, had the highest levels of disease activity, whereas ACPA+ patients had disease activity
that was similar to or lower than that of ACPA− patients, both in the presence and in the absence of RF. When
matched for ACPA levels, patients with highly positive RF had significantly higher disease activity for all composite
indices compared with patients who were RF− (P = 0.0067), whereas ACPA-highly-positive and ACPA-negative
patients matched for RF levels had similar disease activity, again even with the tendency toward lower disease
activity for ACPA+ patients (P = 0.054).
Conclusion: The data presented suggest that the presence of RF has a clear association with higher levels of
disease activity but that the presence of ACPAs has not and even appears to be associated with lower disease
activity.Introduction
Rheumatoid arthritis (RA), a chronic and destructive in-
flammatory disease of the joints, is regarded as an auto-
immune disease based on the presence of various
autoimmune phenomena [1]. The most characteristic ex-
pression of the autoimmune response is the presence of
autoantibodies, such as those directed to immunoglobulin
G (rheumatoid factor, RF), citrullinated peptides (ACPA),
or others [2, 3]. Depending on the stage of the disease, RF* Correspondence: daniel.aletaha@meduniwien.ac.at
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article, unless otherwise stated.and ACPAs can be found in up to 75 % of patients with
RA and occur concomitantly in about 80 % of the
autoantibody-carrying ones [4]. The value of these anti-
bodies is usually related to two important epidemiological
aspects: diagnosis and prognosis. In this regard, they seem
to have similar specificities [4–6], although several reports
have suggested that ACPAs may be more specific and that
the association of RF with progression of joint destruction
may be driven mainly by the concomitantly present
ACPAs [7, 8]; however, these observations have not found
unequivocal agreement [4, 9, 10].
Prognosis usually relates to progression of disease,
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expressed by high swollen joint counts, elevated levels of
acute-phase reactants, or composite measures of disease
activity. RF has been shown to be linked primarily to joint
damage via its association with disease activity, but a more
direct and disease activity-independent effect on joint
damage progression was also found, presumably because
RF has direct effects on osteoclastogenesis and chondro-
cyte activation [11, 12].
Although the association of RF and ACPAs with dis-
ease progression is well investigated, their differential or
independent association with disease activity is not clear.
In the present study, we investigate whether the contri-
bution of ACPAs and RF to disease activity is similar or
related to one of the two. We use data from recent clinical
trials in which both ACPAs and RF had been determined.
Since the purpose is not to investigate therapeutic effects
but rather the cross-sectional associations of RF and
ACPAs with disease activity, we used baseline data of RA
clinical trials, in which patients have active disease and




The trial sponsor kindly provided us with a 90 % random
sample of patient level data from the multi-national,
multi-centre IMAGE trial [13], in which the effects of a
combination of methotrexate (MTX) plus rituximab at
doses of 500 or 1000 mg, given as infusions 2 weeks apart,
were compared with that of MTX monotherapy in MTX-
naïve patients with RA. Since we used only baseline data
of this trial, we combined the baseline data of all arms.
Another sponsor kindly provided us with a 90 % random
sample of patient level data from several multi-national,
multi-centre trials, in which the effects of two doses of goli-
mumab (50 and 100 mg every 4 weeks applied subcutane-
ously), with or without MTX or other disease-modifying
anti-rheumatic drugs, were compared with the effects of ei-
ther newly applied methotrexate (in MTX-naïve patients)
or placebo (in insufficient responders to prior MTX or
other tumor necrosis factor (TNF) inhibitor therapies; Go-
BEFORE, Go-FORWARD, and Go-AFTER trials) [14–16].
For the present evaluation, we mostly pooled the baseline
data of all trial arms of all three studies; in one analysis, we
separately assessed patients with early RA (Go-BEFORE)
and established RA (Go-FORWARD and Go-AFTER).
The available data from all mentioned trials included
demographic characteristics as well as clinical variables,
such as swollen and tender joint counts (SJC and TJC),
patient’s and physician’s global assessments, acute-phase
response levels (C-reactive protein [CRP] and erythro-
cyte sedimentation rate [ESR]), the health assessment
questionnaire disability index, and RF and ACPA levels.From the respective data, composite measures of disease
activity—namely the Disease Activity Score using 28
joint counts (DAS28) using both ESR and CRP and the
simplified and the clinical disease activity indices (SDAI
and CDAI)—were calculated according to established
formulae [17–19]. RF was measured centrally by using
EL-RF/3 from TheraTest Laboratories (Lombard, IL,
USA) and ACPAs by the Diastat enzyme-linked immuno-
sorbent assay manufactured by Axis-Shield (Dundee, UK).
Positivity, or not, of ACPAs and RF obviously will depend
on the used test; false-negative classification of the sero-
logical status is therefore possible, particularly for ACPAs.
Analyses
Our initial analysis was performed in the rituximab data-
base, and additional validation studies were done in the
golimumab dataset. We analysed the effects of RF and
ACPAs on disease activity levels by using two different
approaches: a stratified and a matched analysis.
Stratified analysis
We formed four subgroups according to the presence or
absence of these autoantibody specificities (RF−/ACPA−,
RF+/ACPA−, RF−/ACPA+, and RF+/ACPA+). After calcu-
lating the mean values of baseline demographic and dis-
ease activity variables, including composite indices, as well
as baseline measures of physical function and joint dam-
age, we assessed whether there were any differences across
all groups by Kruskal-Wallis test. If significant differences
were seen in this overall test, we performed pairwise
comparisons between the groups by using Wilcoxon’s
test. A P value of less than 0.05 was considered significant
in all analyses.
Matched analysis
We compared baseline disease activity levels of RF-negative
patients with those of RF-highly-positive ones while we
matched for ACPA levels, age, and duration of RA. This
procedure used propensity scores of the mentioned covar-
iate variables to create 1:1 matches for patients tested
negative versus high positive for RF (or ACPAs in the
other analysis).
We used the Greedy matching algorithms and the
Mahalanobis distance calculation [20]. This approach
controlled for the effect of one serological marker (ACPAs),
while the effect of the other (RF) could be investigated with
a strong contrast (negative versus highly positive). Highly
positive was defined as patients with RF levels greater than
the median of all RF-positive patients. We repeated the
analysis analogously by comparing ACPA-negative and
ACPA-high-positive patients matched by RF levels, age,
and duration of RA.
Given the high co-linearity of RF and ACPAs (approxi-
mately 80 % of seropositive patients are double-positive),
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patients at baseline differed regarding glucocorticoid
use, we performed a subgroup analysis of users versus
non-users regarding their SDAI levels in the rituximab
database.Results
Patient characteristics
Baseline demographic data and disease characteristics
have been published previously for the individual arms
and trials [13–16]. We have pooled arms of the rituxi-
mab IMAGE trial (n = 748) and the golimumab trials
(n = 1370), and the baseline characteristics of these
pooled populations are shown in Table 1.
As depicted in Tables 1, 2, and 3, there was a signifi-
cant (about 75–85 %) overlap between the presence of
RF and ACPAs. This broad overlap is well established,
was already noted in early studies of ACPAs [3, 4], and
is seen to a generally similar extent in our study. In the
IMAGE trial, one of the entry criteria into the study was
the presence of RF or, in its absence, the presence of
erosions and elevated CRP levels [13]. In the golimumabTable 1 Patient characteristics
Rituximab Golimumab All
Patients, number 748 1370 2118
Age, years 47.9 (13.1) 51.2 (12.2) 50.1 (12.6)
Disease duration, years 0.9 (1.2) 7.3 (8.1) 5.1 (7.2)
Female, % 81.2 81.8 81.5
Rheumatoid factor, % positive 87.4 75.4 79.7
ACPAs, % positive 86.0 73.6 78.0
Health assessment questionnaire 1.8 (0.7) 1.5 (0.) 1.6 (0.78)
DAS28-ESR 7.1 (1.0) 5.5 (1.0) 6.3 (1.3)
DAS28-CRP 5.7 (0.9) 5.1 (1.0) 5.3 (1.0)
SDAI 49.6 (14.8) 39.4 (14.6) 43.0 (15.5)
CDAI 46.4 (14.0) 37.2 (13.7) 40.5 (14.5)
Swollen joint count, 0–28 14.5 (6.4) 10.6 (6.0) 12.0 (6.4)
Tender joint count, 0–28 18.2 (7.1) 14.5 (7.41) 15.8 (7.5)
Pain, VAS in mm 63.5 (22.3) 63.0 (22.0) 63.2 (22.1)
Patient global assessment,
VAS in mm
68.5 (21.5) 60.2 (23.4) 63.1 (23.1)
Evaluator global assessment,
VAS in mm
68.2 (17.8) 60.7 (17.8) 63.3 (18.2)
ESR, mm 59.1 (29.5) 41.0 (26.3) 50.7 (29.5)
CRP, mg/dl 3.2 (2.9) 2.1 (2.9) 2.5 (2.9)
Radiographic score 7.5 (11.2) 25.8 (41.6) 17.8 (33.3)
ACPA antibody against citrullinated proteins, DAS28-ESR Disease Activity Score
using 28 joint counts based on erythrocyte sedimentation rate, DAS28-CRP
Disease Activity Score using 28 joint counts based on C-reactive protein, SDAI
simplified disease activity index, CDAI clinical disease activity index, VAS visual
analogue scaletrials, RF or ACPAs were required or, alternatively, damage
and elevated CRP [14, 15].
Stratified analysis
In the initial analysis, we evaluated the IMAGE trial data
by using baseline demographic, disease activity, func-
tional, and radiographic values, stratified according to
the presence or absence of both RF and ACPA. There
were significant differences among the groups regarding
composite measures of disease activity (Fig. 1a) as well
as many disease activity-related variables. The overall P
values are displayed in the column “overall” in Tables 2
and 3. Only if these overall tests were significant, we
moved on to assess the group-wise comparisons. Inter-
estingly, the lowest disease activity levels among all
groups (Table 2, highlighted in bold) were seen for pa-
tients who had ACPAs as their only autoantibody. In
contrast, the highest scores were generally found in
double-positive patients or patients positive for only RF
but not ACPAs, indicating that the presence of RF may
be importantly related to higher disease activity but that
ACPAs may not.
Indeed, RF+/ACPA− (and also RF+/ACPA+) compared
with RF−/ACPA+ patients had significantly higher levels
of DAS28, SDAI, CDAI (Fig. 1), and also swollen and
tender joint counts (Table 2). Moreover, in double-
positive patients, the autoantibody levels were much
higher than the level of RF or ACPAs in single-positive
patients (Tables 2 and 3).
When we repeated these analyses in the golimumab
database, in which patients with various disease dura-
tions and a broad range of medication histories were
comprised (including failure of TNF inhibitors), compar-
able results were obtained: indeed, as shown in Fig. 1b and
Table 3, the lowest disease activity was again observed in
the RF−/ACPA+ group of patients, and significantly higher
disease activity was found in RF+/ACPA− (and even
double-negative) patients for composite measures and
joint counts (Table 3). Similar to the rituximab database,
high levels of disease activity were seen in double-positive
patients, which, as before, appeared driven primarily
by RF, given the higher disease activity in RF+/ACPA−
patients compared with RF−/ACPA+ ones. Moreover,
the differences in acute-phase reactant levels became even
more apparent in the golimumab database, and likewise
differences in physical function. Like in the rituximab
database, autoantibody levels in double-positive patients
were clearly higher compared with single-positive ones.
Matched analysis
Because of the large overlap of seropositivity for these
two antibodies, and in order to control for the potential
effect of autoantibody levels (as indicated above), we
matched RF− and RF-high+ patients for ACPA levels and
Table 2 Patient demographics, disease activity, and functional and structural characteristics according to serological status of RF and
ACPAs: rituximab database
Patient subgroups according autoantibody status P values of direct group comparisons
(1) RF−/ACPA− (2) RF−/ACPA+ (3) RF+/ACPA− (4) RF+/ACPA+ Overall Pairwise comparisons
Patients, number 64 29 40 611 0.48 Not done
Age, years 52.0 (13.5) 49.2 (10.7) 46.1 (14.6) 47.5 (13.0) 0.05 Not done
Disease duration, years 1.0 (1.0) 0.7 (0.9) 0.8 (0.9) 1.0 (1.2) 0.58 Not done
Female, % 82.8 89.7 92.5 80.0 0.15 Not done
Rheumatoid factor, U/ml <15 15.0 (0.0) 170 (199) 517 (854) n.d. Not done
ACPAs, U/ml 2.1 (0.3) 221 (270) 2.9 (1.1) 392 (660) n.d. Not done
Health assessment questionnaire 1.6 (0.6) 1.7 (0.7) 1.8 (0.6) 1.8 (0.7) 0.11 Not done
Disease activity score 28, ESR 6.9 (1.0) 6.6 (0.9) 7.1 (1.2) 7.1 (1.0) 0.0025 (1) vs. (4)*; (2) vs. (3)*; (2) vs. (4)**
Disease activity score 28, CRP 5.6 (0.8) 5.3 (0.8) 5.9 (1.0) 5.8 (0.9) 0.01 (2) vs. (3)**; (2) vs. (4)**
Simplified disease activity index 47.8 (15.0) 42.3 (12.7) 53.1 (16.5) 49.8 (14.7) 0.0076 (2) vs. (3)**; (2) vs. (4)**
Clinical disease activity index 45.0 (14.7) 39.7 (12.2) 49.9 (15.5) 46.6 (13.8) 0.0097 (2) vs. (3)**; (2) vs. (4)**
Swollen joint count 14.2 (6.6) 11.7 (5.9) 16.7 (6.5) 14.5 (6.3) 0.0094 (2) vs. (3)**; (3) vs. (4)**; (2) vs. (4)**
Tender joint count 18.0 (7.0) 14.8 (5.6) 19.4 (8.1) 18.4 (7.1) 0.02 (2) vs. (3)*; (2) vs. (4)**
Pain, VAS 58.9 (21.2) 60.9 (21.5) 61.8 (22.1) 64.2 (22.5) 0.15 Not done
Patient global assessment, VAS 64.3 (19.3) 65.0 (21.6) 68.4 (21.6) 69.0 (21.7) 0.12 Not done
Evaluator global assessment, VAS 64.1 (20.0) 67.2 (12.3) 69.6 (16.3) 68.6 (17.9) 0.35 Not done
ESR 47.5 (25.4) 51.4 (29.0) 54.2 (29.1) 61.0 (29.5) 0.0009 (1) vs. (4)***
CRP 2.7 (2.6) 2.6 (2.0) 3.2 (3.5) 3.3 (2.9) 0.23 Not done
Radiographic score 5.2 (7.9) 7.1 (8.3) 5.77 (11.7) 7.92 (11.6) 0.0066 (1) vs. (4)*; (3) vs. (4)**
n.d. not determined, ACPA antibody against citrullinated proteins, ESR erythrocyte sedimentation rate, CRP C-reactive protein, VAS visual analogue scale
*P < 0.05; **P < 0.01; ***P < 0.001; bold P-values indicate significance at the <0.05 level. For these variables pairwise comparisons ensued
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activity than the RF− group (Fig. 2, left panel inserts). In
contrast, when we matched ACPA− and ACPA-high+ pa-
tients for RF levels, we found higher disease activity in
the ACPA− compared with the ACPA+ patients (Fig. 2,
right panel inserts). These data further supported the
notion that higher disease activity was associated with
the presence of RF and that ACPAs, if present, are asso-
ciated with lower RA disease activity (Fig. 2b, d, f ).
Stratification by glucocorticoid use at baseline
When we compared glucocorticoid users versus non-
users in the rituximab database regarding their SDAI
values, there was no difference between the effects of RF
or ACPA status on the ranking of average disease activ-
ity levels (Additional file 1: Table S1; SDAI results also
presented in Additional file 1: Figure S1).
Discussion
Disease activity is the major determinant of impairment
of physical function and progression of joint damage
[21, 22]. Recognizing elements that influence disease ac-
tivity, therefore, is of particular importance. Autoanti-
bodies have been suggested to increase disease activity
by virtue of immune complex formation with or withoutcomplement activation through binding to Fc or com-
plement receptors (or both) and subsequent increases in
production of pro-inflammatory cytokines [12, 23]. In
the present study, we have shown that baseline disease
activity of patients with RA in clinical trials is positively
associated with the presence of RF but not ACPA. This
conclusion is derived from cross-sectional analyses of
clinical trial patients; all of these patients had active dis-
ease and came from many centres in many countries
and regions. They therefore constitute one of the broadest
representations of RA patients in which such associations
have been studied.
Interestingly, aside from the lower levels of composite
measures of RA disease activity, RF−/ACPA+ patients had
significantly lower levels across most of the individual clin-
ical and laboratory disease activity variables and physical
function compared not only with double-positive patients
but also with those who were RF+/ACPA−. In some in-
stances, ACPA+/RF− patients even had lower scores than
double-negative patients.
On the other hand, similar levels of disease activity
were observed in RF+/ACPA− compared with double-
positive patients, despite the mentioned higher level of
RF in the double-positive group. This may indicate either
that the presence of RF, rather than its level, is the driving
Table 3 Patient demographics, disease activity, and functional and structural characteristics according to serological status of RF and
ACPA: golimumab database
Patient subgroups according to autoantibody status P values of direct group comparisons
(1) RF−/ACPA− (2) RF−/ACPA+ (3) RF+/ACPA− (4) RF+/ACPA+ Overall Pairwise comparisons
Patients, number 268 68 93 937 0.48 Not done
Age, years 51.7 (12.8) 48.1 (14.4) 52.2 (12.0) 51.2 (11.9) 0.15 Not done
Disease duration, years 6.8 (8.5) 4.9 (5.7) 6.4 (6.9) 7.8 (8.2) <0.001 (1) vs. (4)**; (2) vs. (4)***
Female, % 82.1 80.9 86.0 81.4 0.74 Not done
Rheumatoid factor 9.3 (2.8) 10.8 (2.6) 96 (162) 190 (275) n.d. Not done
ACPA 2.1 (0.4) 112 (167) 2.5 (0.9) 225 (409) n.d. Not done
Health assessment questionnaire 1.5 (0.6) 1.3 (0.7) 1.4 (0.7) 1.5 (0.7) 0.02 (1) vs. (2)*; (2) vs. (4)*
Disease activity score 28 (ESR) 5.6 (1.0) 5.1 (1.1) 5.6 (0.8) 5.5 (1) 0.06 Not done
Disease activity score 28 (CRP) 5.1 (1.0) 4.7 (1.0) 5.1 (1.0) 5.1 (1) 0.007 (1) vs. (2)***; (2) vs. (3)*; (2) vs. (4)**
Simplified disease activity index 40.7 (14.8) 33.4 (12.4) 40.0 (16.3) 39.3 (14.3) 0.002 (1) vs. (2)***; (2) vs. (3)*; (2) vs. (4)***
Clinical disease activity index 38.7 (14.1) 31.7 (12.2) 37.6 (14.9) 37.1 (13.4) 0.002 (1) vs. (2)***; (2) vs. (3)*; (2) vs. (4)***
Swollen joint count 10.7 (6.4) 8.7 (4.7) 10.9 (6.4) 10.7 (5.9) 0.06 Not done
Tender joint count 15.7 (7.9) 11.9 (6.9) 15.1 (8.0) 14.3 (7.2) 0.001 (1) vs. (2)***; (1) vs. (4)**; (2) vs. (3)*; (2) vs. (4)**
Pain (VAS) 65.2 (19.5) 61.1 (25.0) 60.4 (23.6) 62.7 (22.3) 0.41 Not done
Patient global assessment (VAS) 62.2 (22.1) 57.0 (25.0) 59.3 (24.7) 59.9 (23.5) 0.43 Not done
Evaluator global assessment (VAS) 60.7 (17.4) 53.6 (19.1) 57 (18.1) 61.5 (17.6) 0.003 (1) vs. (2)**; (3) vs. (4)*; (2) vs. (4)**
Erythrocyte sedimentation rate 37.1 (25.7) 38.0 (22.7) 40.1 (26.4) 42.8 (26.8) 0.08 Not done
C-reactive protein 1.9 (2.8) 1.8 (2.5) 2.3 (4.4) 2.2 (2.7) <0.001 (1) vs. (4)***; (3) vs. (4)*; (2) vs. (4)*
Radiographic score 15 (26) 24.3 (47.2) 18.3 (31.7) 29.6 (44.9) <0.001 (1) vs. (4)***; (3) vs. (4)*
n.d. not determined, ACPA antibody against citrullinated proteins, ESR erythrocyte sedimentation rate, CRP C-reactive protein, VAS visual analogue scale
*P < 0.05; **P < 0.01; ***P < 0.001; bold P-values indicate significance at the <0.05 level. For these variables pairwise comparisons ensued
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effect of RF levels plus some “protective” effect of ACPA
reducing higher disease activity due to higher RF levels in
double-positives, therefore causing an apparent similarity
of disease activity in these two groups. The latter hypoth-
esis is clearly supported by two facts, the first of which
is the comparison of ACPA+ and ACPA− patients who
are seronegative for RF. Here, in the absence of RF, the
presence of ACPAs is also associated with lower levels
of disease activity; the second fact is the matched analyses,
which controlled for the level of the respective other
autoantibody.
The important role of RF, and not of ACPA, in relation
with higher levels of disease activity, was also implied in
another recent study, in which the authors have revealed
that RF+ patients regardless of ACPA status compared
with RF−/ACPA+ patients exhibited not only higher disease
activity but also higher levels of pro-inflammatory cytokines
[24]. However, in that study, it was also hypothesized that
ACPAs have a synergistic effect in the presence of RF re-
garding disease activity, a finding which can be neither sup-
ported nor ruled out by the present study.
Based on the epidemiological findings of our study,
some translational explanations can be used to understandthe clear relationship of RF with disease activity as
well as its absence for ACPAs. Firstly, as assessed in
routine practice and clinical trials, RF is of IgM isotype
whereas ACPAs are mostly IgG antibodies; IgM isotype
activates complement to a much larger extent than IgG
[25], thus potentially leading to a stronger secondary
inflammatory response via inflammatory complement
breakdown products or complement-receptor-mediated
macrophage activation or both [26–28]. In this setting,
ACPAs might preferentially activate inhibitory Fcγ-
receptors and thus mitigate the inflammatory response
[29]. At the same time, however, it is conceivable that
IgM ACPAs also exist but that current tests are able to
detect IgG only.
Secondly, ACPAs likely represent products of long-
lived memory plasma cells [30], whereas RF may be at
least partly produced by a particular subset of B lympho-
cytes, B-1 cells; the former may have less plasticity and
responsiveness to variations of the disease process or
might be less involved in cell-cell interactions in RA
than the latter [31, 32]. However, it should be noted that
the existence of B-1 cells in humans has been a matter
of some debate, although evidence of their existence is
increasing [33–35] and they have been related especially
Fig. 1 Disease activity at baseline of clinical trials stratified by the presence or absence of rheumatoid factor (RF) or anti-citrullinated peptide
antibodies (ACPAs). a Rituximab database (IMAGE trial of early RA). b Golimumab database (several trials on RA patients with various
disease durations). Please see Table 2 for details on numbers and statistics. CDAI clinical disease activity index, DAS28-ESR Disease Activity Score
using 28 joint counts-erythrocyte sedimentation rate, RA rheumatoid arthritis, SDAI simplified disease activity index
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here again epidemiological findings support their exist-
ence, as RF levels may change substantially in patients
responding to therapies, but ACPA levels do not [37,
38]. This notion is reinforced by the high correlation of
the presence of RF with comorbidity and cardiovascular
death [39, 40]. Also, RF has been shown to induce pro-
inflammatory cytokines like TNF [41]. All of these find-
ings together support concepts that RF, and not ACPAs,
is the main serological inflammatory player but that
ACPAs on their own not only may not fuel RA disease
activity but even may mitigate it. This finding should be
clearly distinguished from the well-established association
of ACPAs with radiographic damage [4]. Moreover, ACPAs
have been suggested to have a direct effect on osteoclasto-
genesis, and therefore their association with joint damage
may be independent of disease activity [42].
The broad overlap of RF and ACPAs has been a practical
limitation for any study investigating differential effects of
each of these antibodies and is also a limitation of our
study. Indeed, the small sample size of single seropositive
patients in the stratified comparisons may put the analysisat risk for incorrectly failing to reject the null hypothesis of
no association of antibodies with disease activity. Since our
results were statistically significant, a potentially limited
sample size is obviously not relevant. In addition, we took
an unprecedented approach to account for this co-linearity
of RF and ACPAs by the above-matched analysis. Finally,
the initial results obtained in one trial dataset were
confirmed in a totally unrelated second large clinical
trial database.
Since the data are based on clinical trials, another po-
tential limitation may be selection bias related to the
typical inclusion and exclusion criteria. This selection
bias might affect the generalisability of the results. Par-
ticularly, results cannot be generalised to patients who
have very little or no disease activity but in whom these
associative analyses with disease activity would not be
possible for lack of active disease. In all trials, some
serological criteria and some minimal disease activity
requirements applied. However, these two were always
independent and never conditional. For the IMAGE
trial, RF seronegativity at baseline was allowed only if there
was evidence of erosive disease. Since ACPAs were not
Fig. 2 (See legend on next page.)
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Fig. 2 Disease activity distributions for the simplified disease activity index (SDAI) at baseline according to rheumatoid factor (RF) or anti-citrullinated
peptide antibodies (ACPAs) or both. Probability plots of levels of disease activity according to the SDAI. a, c, e Distributions of baseline SDAI values
by RF status (negative versus high positive) in patients matched for ACPA, age, and duration (higher disease activity in RF-positive patients; overall
P = 0.0067). b, d, f Distributions of baseline SDAI values by ACPA status (negative versus highly positive) in patients matched for RF levels, age, and
duration of RA (higher disease activity in ACPA-negative patients; overall P = 0.054). Data are separated by trials for IMAGE trial (a, b), GO-BEFORE (c, d),
and combined GO-FORWARD+GO-AFTER (e, f)
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the autoantibodies (sizes of the four groups) is not neces-
sarily reflective of a general RA population. We can never-
theless make the points for the validity of the results in
the IMAGE trial by using the following arguments: firstly,
in golimumab trials, ACPAs or RF (or both) were required,
thus confirming the data of the IMAGE trial in another
trial with different serological inclusion requirements;
secondly, patients negative for RF were required to have
elevated CRP and joint damage, thus biasing ACPA+/RF−
and ACPA−/RF− patients toward higher rather than lower
disease activity compared with the respective RF+ groups.
The opposite was observed. That this was the reverse
with the ACPA+/RF− population further supports our
conclusion, while the comparably high activity seen in
double-negative patients may indeed be due to the—in-
dependent—prerequisite to have higher levels of disease
activity. Notably, compared with double-positive pa-
tients, single-positive patients had lower levels of that
respective autoantibody (about 50 % less), suggesting
that the presence of both autoantibodies may be related
to a higher autoimmune thrust than the presence of
just one. Also, disease activity of RA is inherently fluc-
tuant and, therefore, assessing it at a single time point,
as analysed here, may not provide the full picture; how-
ever, the large group of patients studied here inherently
has an averaging effect and, in addition, patients in
clinical trials have to present with active disease at a
pre-screening visit as well as the baseline visit, ensuring
some degree of persistence in disease activity. Further-
more, patients in clinical trials come from many centres
throughout many regions, thus reducing the potential
selection bias that may be inherent to studies of pa-
tients coming from a single or just few centres. Finally,
many of the potential differences were accounted for by
the additional matched analysis.
The cross-sectional character of our study may be
regarded as a limitation because antibody levels may
change over time, particularly under the influence of ef-
fective therapy, although ACPA levels fluctuate less than
RF levels [38]. However, the purpose here was to look at
associations with autoantibody status and not with changes
during therapy. We intentionally focused only on baseline
data in order to prevent confounding by treatment. Also, in
a separate analysis, glucocorticoid use at baseline did nothave an influence on the observed results. In addition, the
similarity of the results in the different trial populations,
capturing MTX-naïve patients with early RA on the one
hand (rituximab database) and patients across all lengths of
disease duration and prior drug experience (golimumab
database) on the other, was highly confirmatory and clearly
adds to the generalisability of our findings. It is nevertheless
important to bear in mind that, although the present data
came from two large independent databases, analyses from
additional databases in independent studies will be needed
to fully confirm our conclusions.
Conclusions
The presence of RF appears to have a clear association
with higher levels of disease activity, whereas the pres-
ence of ACPAs is associated with lower disease activity,
although this was observed only as a trend. The data
further imply that therapeutic strategies in RA should
focus not only on classic variables of disease activity
but also on the presence of RF. As seroconversion into
an autoantibody-negative state is attainable for RF, this
should be a therapeutic goal, and lack of seroconversion a
potentially decision-driving situation. In contrast, serocon-
version has not yet been frequently seen for ACPAs
[38, 43]. ACPAs, on the other hand, should be considered
regarding structural outcomes, on which they may have
an effect independent of disease activity.
We consider several relevant points of our findings for
the practicing rheumatologist. Firstly, the data reveal that
RF determination is important, and the presence of RF is
related to higher levels of disease activity. Secondly, the data
reveal that aside from their diagnostic value as detailed
in the new American College of Rheumatology-European
League Against Rheumatism (ACR-EULAR) classification
criteria as well as their prognostic value regarding struc-
tural progression, ACPAs are not of major relevance
regarding the risk of a highly active disease process (which
is known to drive progression). Thirdly, the large overlap
with RF positivity questions the value of determining
ACPAs in the course of the disease, making it potentially
relevant only for RF-negative patients or low-titre RF-
positive patients, as previously suggested [4, 44]. Given the
data at hand, only determining ACPAs without assessing
RF, as has also been proposed by some [45], may be an un-
justified approach.
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Additional file 1: Figure S1. Disease activity at baseline in the
rituximab database (IMAGE trial of early rheumatoid arthritis). Stratified
analysis by the presence or absence of rheumatoid factor (RF) and of
anti-citrullinated peptide antibodies (ACPA) (x-axis categories) as well as
by the use, or not, of glucocorticoids. SDAI simplified disease activity
index. Table S1. Disease activity indices at baseline in subgroups by RF
and ACPA positivity, as well as by glucocorticoid use, or not. ACPA antibody
against citrullinated peptides, CDAI clinical disease activity index, DAS Disease
Activity Score, RF rheumatoid factor, SDAI simplified disease activity index.
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